hIBStory
1963
Arturo Licenziati begins his career in the pharmaceutical industry.
He supervises the establishment of the Belgian subsidiary of the Zambon Group, developing and expanding the company in central Europe.
1969
Arturo Licenziati takes up the position of Vice President of Merck Sharp & Dohme (MSD).
1970
Arturo Licenziati is called back to Zambon, where he develops all the research, production and commercial processes of the Swiss subsidiary.
1982
REGISTRATION of:
- Chondrosulf capsules
1985
In 1985, Arturo Licenziati sets up his own business and acquires a small Swiss company, founded in Lugano in 1945, whose corporate name is – and remains – IBSA Institut Biochimique SA. The operations of this small laboratory are concentrated mainly in Japan.
1986
1987
REGISTRATION in Switzerland of:
- Solmucol granules
IBSA obtains its first patent for diclofenac epolamine (DHEP).
1988
REGISTRATION in Switzerland of:
- Myrtaven capsules
- Ialugen cream
- Ialugen medicated gauze
By investing 6 million francs, Arturo Licenziati renews the production lines, creates a Marketing and a R&D department, activating collaborations with research centres in Italy, France and the UK.
He also starts the partnership with Laboratoire Genevrier (today IBSA France).
1989
REGISTRATION in Switzerland of:
- Solmucol tablets
1991
REGISTRATION in Switzerland of:
- Flector gel
- Chondrosulf tablets
1992
Arturo Licenziati begins to lay the foundations for what will be the largest subsidiary of the IBSA Group (IBSA Italy), by opening the IBSA Farmaceutici mailbox.
1993
IBSA Pharma Kft. (IBSA Hungary) is established.
1993
REGISTRATION in Switzerland of:
- Flector Tissugel medicated plaster 180
- Solmucol syrup
Learn more about the history of Flector Tissugel
Learn more about the history of Solmucol
1995
REGISTRATION in Switzerland of:
- Diclofenac epolamine granules
1996
REGISTRATION in Switzerland of:
- Fostimon (FSH) 75, 150, 225, 300 IU
- Meriofert (hMG) 75, 150, 225, 300 IU
1997
REGISTRATION in Switzerland of:
- BioVigor (B12 and four amino-acids in syrup)
1998
The headquarters is moved from Massagno to Collina d’Oro, where it is still located today.
1998
IBSA obtains a patent for hormonal preparations.
The Qingdao Huashan Biochemical production site (IBSA China) is established in China.
Learn more about IBSA's history in China
1999
Fire in Massagno. The factory is half destroyed, with damage estimated at around 20 million francs. The severity of the event drives the purchase of two new buildings in Manno and Lamone. In Lamone, IBSA builds a site entirely dedicated to the production of gonadotropins and progesterone, with an investment of 25 million francs.
2000
The laboratories in Manno and Lamone, Switzerland, are inaugurated, as well as those of Qingdao Huashan Biochemical, China.
2001
2002
The new production site in Lamone (Switzerland) is inaugurated.
Discover the history of the Lamone production plant
2002
A new production site, Rizhao Lanshan Biochemical (IBSA China), is established.
2003
IBSA Slovakia s.r.o. (IBSA Slovakia) is established.
2005
REGISTRATION in Italy of:
- Choriomon (hCG) with 250, 1000, 2000, 5000, 10.000 IU
2006
A new plant for the production of soft capsules is opened in Manno (Switzerland).
2006
.jpg)
REGISTRATION in Switzerland of:
Tirosint (T4) softgel capsules
REGISTRATION in US of:
Tirosint (T4) softgel capsules
2007
IBSA İlaç San Ve Tic. Ltd. Şti. (IBSA Turkey) is established.
2007
REGISTRATION in US of:
- Flector
IBSA is the first European pharmaceutical company to introduce an anti-inflammatory into the US market.
2008
REGISTRATION in Italy of:
- Tirosint (T4) multidose oral solution
IBSA enters the US Market with Flector Patch (pain and inflammation) and Tirosint (endocrinology).
Learn more about the history of Flector Tissugel
2008
IBSA Foundation for Children is established.
2009
Bouty Healthcare (production site in Cassina de’ Pecchi, Italy) is acquired.
2010
Official birth of IBSA Farmaceutici Srl (IBSA Italy), with 50 employees.
2011
IBSA Poland sp. z o.o. (IBSA Poland) is established.
2011
REGISTRATION in Italy of:
- Tirosint (T4) singledose
2012
2013
.png)
REGISTRATION in Italy of:
- Tirosint (T4) softgel capsules
2014
IBSA Nordic ApS (IBSA Nordic) is established.
2016
IBSA Pharma Inc. (IBSA USA) is established.
2016
REGISTRATION in US of:
- Tirosint Sol (T4) single dose
2018
IBSA Pharma HK Ltd. (IBSA Hong Kong) is established.
2018
REGISTRATION in Switzerland of:
- Tirosint Sol (T4) single dose
2019
The Instituto Bioquímico Ibérico IBSA SL (IBSA Iberia) is established.
2020
IBI, spol. s r.o. is acquired and IBSA Pharma s.r.o. (IBSA Czechia) is established.
2020
REGISTRATION in Italy of:
- Levotirsol (T4) single dose
2021
Laboratoire Genevrier is acquired, becoming IBSA Pharma SAS (IBSA France).
IBSA Pharma GmbH (IBSA Austria), IBSA Pharma BV (IBSA Netherlands) and Yaral Pharma Inc. (US) are established.
2022
Pharmasure is acquired and IBSA Pharma Ltd. (IBSA UK) is established; Marckyrl Pharma is acquired and IBSA Pharma GmbH (IBSA Germany) is established. IBSA Pharma Srl (IBSA Belgium) and IBSA Pharma Oü (IBSA Baltic) are established.
The cosmos production site – the largest production facility of the IBSA group – is inaugurated, in Lugano.
2023
IBSA Pharma Pte Ltd. (IBSA Singapore) is established.
2024
.png)
Building on its experience, IBSA looks to the future with determination, investing in a new organisational structure to tackle tomorrow's challenges on a solid and structured basis.
2025
IBSA celebrates Arturo Licenziati’s 40 years of leadership.
